Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update | Taiwan News | Sep. 23, 2025 13:01

Contributing sentiments towards policy:

57% : [5] Ward et al., WMS 2022, FP.27 - Poster 71. Link.
53% : AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Commission (EC), in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), in China by the National Medical Products Administration (NMPA) and Hong Kong by the Department of Health (DoH).
45% : These relate to employee expenses as the Company expands activities to support the commercialization of AGAMREE, offset by decreases in development expenses due to non-recurring longer-term study expenses closing in the prior year.
44% : Sperogenix non-reimbursed commercial rollout commences In China, partner Sperogenix commenced a non-reimbursed commercial rollout of AGAMREE in September 2025, in addition to the earlier started Early Access Program.
40% : Priorities for the second half of 2025 are to expand sales in the non-reimbursed market.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.